NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Sol-Gel Technologies Ltd. (SLGL) Stock Analysis

Sol-Gel Technologies Ltd. (SLGL) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

SLGL

$65.72

−$0.09 (−0.14%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SLGL with… →

SLGL Key Statistics

As of Oct 21, 2026
Trading
Open
$66.44
Previous Close
$65.81
Day's Range
64.50–69.19
52-Week Range
28.81–97.97
Volume
59.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.15
Valuation
Market Cap
$215.17M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
119.87
EPS (ttm)Profit attributable to each share over the last twelve months.
−5.61
Financials (FY)
Revenue (FY)
$19.39M+68.04%
Net Income (FY)
−$6.13M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
3.27M
1-Year Return
+64.30%
Dividend and dates
Earnings Date
November 19, 2026estimated
Avg Volume
53.76K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, SLGL closed at $65.72, +64.30% over 1 year.

Sol-Gel Technologies Ltd. (SLGL) has a market capitalization of $215.17M.

In fiscal 2025, SLGL reported revenue of $19.39M.

SLGL Stock Return by Calendar Year

Sol-Gel Technologies Ltd. (SLGL) return since Feb 2018: what $10,000 became

1 year
$10,000 $16,430
+64.30%
5 years
$10,000 $7,270
−27.30%
Since Feb 2018
$10,000 $4,818
−51.82%

If you had invested $10,000 in Sol-Gel Technologies Ltd. (SLGL) at the close on February 1, 2018, the earliest close on record here, it would have been worth $4,818 at the close on October 21, 2026: −51.82% in total, −8.04% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+55.96%
2025+353.12%
2024−15.84%
2023−75.77%
2022−38.38%
2021−24.41%
2020−42.92%
2019+184.88%
2018 (partial year)−55.87%

As of October 21, 2026.

SLGL Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$19.39M−$6.13M−31.6%
2024$11.54M−$10.58M−91.7%
2023$1.55M−$27.24M−1,752.8%
2022$3.88M−$14.92M−384.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$19.39M—−$7.54M−$6.13M−31.6%
2024$11.54M—−$12.01M−$10.58M−91.7%
2023$1.55M—−$29.31M−$27.24M−1,752.8%
2022$3.88M—−$16.24M−$14.92M−384.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SLGL Valuation vs Biotechnology Median

Median of 608 stocks
MetricSLGLBiotechnology medianvs median
P/S ratio119.8713.309.0x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Sol-Gel Technologies Ltd. (SLGL) carries a market capitalisation of $215.17M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 28 employees.

The most recent close on file for SLGL is $65.72, dated October 21, 2026. That is −$0.09 (−0.14%) against the previous close. Over the past 52 weeks the price has ranged from $28.81 to $97.97. The latest close sits 128.12% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $19.39M. That is +68.04% against the prior fiscal year, when revenue was $11.54M. The same year closed with a net loss of $6.13M. Trailing earnings per share are −5.61.

Across the 4 fiscal years on file, revenue moves from $3.88M in 2022 to $19.39M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 119.87 times revenue. On price-to-sales that is 9 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.15. Daily returns over the trailing 8 years annualize to a volatility of 134.53%. The trailing one-year total return is +64.30%. Across 5 years the annualized return works out at −6.18%.

Growth & Income

No dividend is on file for SLGL.

2026 is still running; the total return is +55.96% year to date. Across the complete calendar years on file, 2025 returned +353.12% and 2023 returned −75.77%. Of the 7 complete calendar years on file, 2 finished higher.

Peer Comparison

Sol-Gel Technologies Ltd. (SLGL) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Sol-Gel Technologies Ltd. SLGL $215.17M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Sol-Gel Technologies Ltd. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Visit website →